In the present study, our results, that HDAC inhibitor S11 inhibited the tumor growth of cisplatin-resistant NSCLC cells and malignant behavior through upregulating OAZ1, prompted us to evaluate the effectiveness of combination therapy as an approach for cisplatin-resistant NSCLC. Here, HDAC9 is linked to non-small cell lung carcinoma.